y, efficacy or other reasons, the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory authorities, and the risks identified under the heading ???Risk Factors??? in Synageva???s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the ???SEC???) on November 4, 2013 and other filings Synageva periodically makes with the SEC, and o